Studies

Below is a list of the ongoing clinical research trials in the Department of Dermatology and Dermatologic Surgery:

Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate to Severe Atopic Dermatitis  

  • Population: Patients aged eighteen to fifty five years old
  • Study Condition: Moderate to severe atopic dermatitis
  • Study Design: The main purpose of this study is to learn whether Lebrikizumab could impact how effective certain vaccines may be and how effective and safe the study drug is in patients with moderate-to-severe AD compared with placebo. A placebo is an inactive material that looks like the study drug but does not contain any active study drug. The study duration is approximately 32 weeks, and participants will need to come to the study center at least 7 to 11 times over this period. This study will also include 2 vaccines commonly used in adults with moderate-to-severe AD: meningococcal vaccines (MCV) and tetanus, diphtheria, and pertussis (Tdap).
  • Subjects may be reimbursed for study related travel expenses.

A Study to Investigate the Effectiveness and Safety of ARQ-151 Cream 0.15% in Subjects with Atopic Dermatitis

  • Population: Participants aged six and older
  • Study Condition: Mild to moderate eczema
  • Study Design: This is a four-week placebo-controlled study. Participants will be randomly chosen to either receive ARQ-151 or a vehicle cream. The vehicle cream or placebo is a “dummy” cream that is made from the same base product that is used to make ARQ-151, but it does not contain any active study drug. Participants will apply the ARQ-151 or vehicle once every day for one month.
  • Compensation may be provided 

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate to Severe Atopic Dermatitis

  • Population: Patients aged twelve years and older
  • Study Condition: Moderate to severe atopic dermatitis
  • Study Design: This is a Phase III clinical trial assessing the efficacy and safety of Nemolizumab, an anti-IL-31 receptor monoclonal antibody, injected subcutaneously every 4 weeks. In the initial treatment period, patients will be randomized 2:1 to receive Nemolizumab 30 mg or placebo every four weeks for a total of 48 weeks of treatment. Depending on response to study medication, at week 16 patients may be re-randomized (1:1:1) into the maintenance period to receive either Nemolizumab (every four weeks or every eight weeks) or placebo every four weeks for an additional 32 weeks. The study can last up to 28 or 60 weeks based on the clinical response of the subjects to the treatment at the end of the initial treatment period (week 16). Participants who complete this trial will be given the option to enroll into an open-label long term extension study where all subjects will receive Nemolizumab.
  • Compensation is provided for time and travel

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate to Severe Atopic Dermatitis

  • Population: Patients aged twelve years and older
  • Study Condition: Moderate to severe atopic dermatitis
  • Study Design: This study can last up to 116 weeks. Participants will receive injections of nemolizumab every four weeks for a treatment period of 104 weeks.
  • Compensation is provided for time and travel

Prurigo Nodularis 

A Study to Assess the Efficacy and Safety in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation

  • Population: Patients aged eighteen years and older
  • Study Condition: Generalized prurigo nodularis (having at least ten prurigo nodules in two or more distinct anatomical locations on the body)
  • Study Design: Sponsored by Trevi Therapeutics this study is to evaluate Nalbuphine ER tablets, an opioid acting as an antagonist at the mu receptor and agonist at the kappa receptor, deeming it a non-controlled substance developed to alleviate itch. The total length of the study is 56 weeks. During the first fourteen weeks, patients will be randomized 1:1 to receive either Nalbuphine ER or placebo. This will be followed by a 38 week open label period where patients will be guaranteed to receive Nalbuphine ER tablets.
  • Compensation is provided

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of an Investigational Drug in Reducing Pruritus in Subjects with Prurigo Nodularis

  • Population: Patients aged eighteen to eighty years old
  • Study Condition: Moderate to severe prurigo nodularis (at least twenty nodules in two or more distinct anatomical locations on the body)
  • Study Design: Participants will be randomly assigned to receive different dosing regimens of the investigational drug or a “dummy” substance that has no active drug in it but looks exactly like the investigation drug. This study will last up to one year.
  • The investigational drug or “dummy” substance will be injected under the skin for a treatment period, followed by an open-label extension period where the investigational drug will be provided for the remainder of the study participation period.
  • Compensation is provided

Lamellar Ichthyosis 

A Study to Access the Safety, Efficacy, and Systemic Exposure of Trifarotene (CD5789) Cream HE1 in Adults and Adolescents with Autosomal Recessive Ichthyosis with Lamellar Scale

  • Population: Patients aged twelve years or older
  • Study Condition: Lamellar ichthyosis
  • Study Design: Sponsored by Mayne Pharmaceuticals, this study is evaluating CD5789 or Trifarotene, a novel retinoic acid receptor agonist topical cream. Patients will be randomized 1:1:1 to receive lower dose Trifarotene, higher dose Trifarotene, or vehicle/placebo to be applied twice weekly for up to twelve weeks. Participants who complete this trial will be given the option to enroll into a twelve week long term extension where Trifarotene will be provided.
  • Compensation is provided

Psoriasis 

A Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis

  • Population: Patients aged six to seventeen years old
  • Study Condition: Moderate to severe plaque psoriasis
  • Study Design: Sponsored by Amgen, this study aims to evaluate the efficacy, safety, and tolerability of oral Apremilast compared with a placeboin Pediatric patients. The study will last up to 71 weeks. For the first 16 weeks, patients will be randomized 2:1 to receive either Apremilast or placebo. After week 16, all participants will be given Apremilast for 36 weeks. Participants who complete this trial will be given the option to enroll into a long term extension where Apremilast will be provided.
  • Compensation for your time, travel and food will be provided

Hidradenitis Suppurativa 

Please check back for upcoming hidradenitis suppurativa studies 

Vitiligo

Please contact Dr. Caroline Porter for more information regarding ongoing hidradenitis suppurativa studies

Email: portecar@musc.edu

Phone: 843-876-0110